01 / DESIGN
What was studied?
MMPOWER-3 randomized 218 participants with genetically confirmed primary mitochondrial myopathy to elamipretide or placebo for 24 weeks.
02 / FINDINGS
What did the researchers report?
The study did not show an improvement over placebo in its primary endpoints: six-minute walking distance and total fatigue score. Most adverse events were mild or moderate.
03 / LIMITS
How should it be interpreted?
Tolerability is not the same as demonstrated efficacy. These findings concern this disease population and study design; they do not establish benefits for healthy aging, athletic performance or other untested uses.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.